Clinical Trial Update: Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sorafenib in advanced or metastatic urothelial cancers of the urinary tract (including bladder, renal pelvis, and ureter); results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma of the Bladder
• Urothelial Carcinoma of the Renal Pelvis
• Urothelial Carcinoma of the Ureter

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-09-03